NIKKEI 225
38,471.20 -761.60 (-1.94%) HANG SENG
16,248.97 -351.49 (-2.12%) CRUDE OIL
85.30 -0.11 (-0.13%) GOLD FUTURES
2,414.10 +31.10 (+1.31%) DOW
37,851.16 +116.05 (+0.31%) Bitcoin GBP
50,494.73 -1,418.05 (-2.73%)
KORU Medical Systems, Inc. (KRMD)
| Previous close | 2.0800 |
| Open | 2.1000 |
| Bid | 2.1100 x 100 |
| Ask | 2.1900 x 100 |
| Day's range | 2.0500 - 2.1700 |
| 52-week range | 1.9780 - 4.4800 |
| Volume | |
| Avg. volume | 94,912 |
| Market cap | 99.666M |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
KORU Medical Systems Announces Successful Appeal in EU Notified Body Review
MAHWAH, N.J., April 11, 2024--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a successful appeal related to an ongoing audit by its notified body in the EU, The British Standards Institute (BSI).
- Business Wire
KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference
MAHWAH, N.J., March 18, 2024--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce data on the impact of the Freedom Infusion System on subcutaneous immunoglobulin (SCIg) therapy for primary immunodeficiency diseases (PIDD) to be presented at the National Home Infusion Assoc
- Business Wire
KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance
MAHWAH, N.J., March 13, 2024--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023. The Company also issued guidance for the full year 2024.
